Lupin Introduces Patient Support Programme, Jeet to Raise Awareness of Cardiovascular Disease among Patients

Lupin Limited announced the launch of Jeet, a patient support programme dedicated to heart health. The launch of the initiative coincides with India's 77th Independence Day, symbolising freedom from disease-related stress and a journey towards a happier and healthier life. Jeet will be a trusted partner in cardiovascular care, providing a variety of services such as medical cost savings, disease counselling, medication reminders, and lifestyle support.

Jeet is available via the Play or App Store, as well as the website. Jeet takes a comprehensive approach to improving the doctor-patient relationship by increasing awareness of cardiovascular diseases and associated co-morbid conditions. The programme includes elements intended to encourage healthier lifestyle choices as well as support and care for a healthy heart. Jeet ensures that medication reminders are sent out on time and promotes daily health and wellness activities, such as interactions with patients. Rewards and reminders are important features. Jeet incentivizes healthier lifestyle choices and medication adherence by allocating heartbeats for consistent, timely adherence. Jeet allows you to upload prescriptions and schedule tasks to generate timely alerts, ensuring medications are taken on time and reducing the likelihood of missed doses. "Technology has the potential to improve outcomes by increasing patients' awareness of their condition and possible lifestyle interventions," said Rajeev Sibal, president India Region Formulations, Lupin. Our primary goal at Jeet is to provide patients with comprehensive support services that improve their medication adherence, lifestyle adoption, and beyond. Our mission is to empower patients to live healthier and happier lives.

Jeet exemplifies Lupin's unwavering commitment to patient-centeredness and improving healthcare in India." Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.